Skip to content
Study details
Enrolling now

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Case Comprehensive Cancer Center
NCT IDNCT06904482ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

36

Study length

about 4.5 years

Ages

18+

Locations

1 site in OH

What this study is about

Researchers are testing if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease. The trial is testing a treatment that involves transplanting cord blood and haplo-identical grafts together.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Haplo-Identical / Cord Blood Transplant

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Progression free survival(PFS) at 6 months after transplant

Secondary: Graft versus host disease relapse free survival at 1 year after transplant, Graft versus host disease relapse free survival at 2 years after transplant, Graft versus host disease relapse free survival at 3 years after transplant, Overall survival at 2 years after transplant, Overall survival at 3 years after transplant, Overall survival(OS) at 1 year after transplant, Progression free survival at 1 year after transplant, Progression free survival at 2 years after transplant

Body systems

Oncology